Martine A Rothblatt, Director, Chairperson & CEO, on August 03, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,902,569. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1082554/000110657826000112/xslF345X05/primarydocument.xml
Michael L Goldstone, Senior Vice President, General Counsel and Corporate Secretary, on July 30, 2026, sold 4,500 shares in Rush Enterprises (RUSHA) for $365,243. Following the Form 4 filing with the SEC, Goldstone has control over a total of 12,590 Class A common shares of the company, with 12,590 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1012019/000143774926025490/xslF345X05/rdgdoc.xml
Steven L Keller, CFO & Treasurer, on July 30, 2026, sold 22,500 shares in Rush Enterprises (RUSHA) for $1,817,055. Following the Form 4 filing with the SEC, Keller has control over a total of 84,374 Class A common shares of the company, with 84,374 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1012019/000143774926025491/xslF345X05/rdgdoc.xml
William M Rusty Rush, 10% Owner, Director, CEO, President and Chairman of the Board, on July 31, 2026, sold 78,750 shares in Rush Enterprises (RUSHA) for $6,380,712. Following the Form 4 filing with the SEC, Rush has control over a total of 174,155 Class A common shares of the company, with 174,155 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1012019/000143774926025492/xslF345X05/rdgdoc.xml